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procedural transmission of SARS-CoV-2 between patients and staff. The indication for
any cardiac imaging test should be carefully considered, and only those tests
considered essential to patient care performed. The scope of these EACVI
recommendations is to summarise how these challenges may be addressed during the
pandemic. In particular we focus upon bold prioritisation and provide specific
indications and recommendations on how to perform an echocardiogram during the
pandemic whilst safeguarding both patient and staff safety.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
COVID -19 pandemic and cardiac imaging. EACVI recommendations on 
precautions, indications, prioritisation and protection for patients and 
healthcare personnel.  
 
Helge Skulstad1,2, Bernard Cosyns3, Bogdan A Popescu4, Maurizio Galderisi5, Giovanni Di 
Salvo6, Erwan Donal7, Steffen Petersen8,9, Alessia Gimelli10, Kristina H Haugaa1,2, Denisa 
Muraru11, Ana G Almeida12, Jeanette Schulz-Menger13,14,15, Marc R Dweck16, Gianluca 
Pontone17, Leyla Elif Sade18, Bernhard Gerber19, Pal Maurovich-Horvat20, Tara Bharucha21, 
Matteo Cameli22, Julien Magne23,24, Mark Westwood9, Gerald Maurer25, Thor Edvardsen1,2 
 
1. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 
2. Faculty of Medicine, University of Oslo, Oslo, Norway. 
3. Centrum voor Hart en Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel, Vrij Universiteit 
van Brussel, Brussels, Belgium. 
4. Department of Cardiology, University of Medicine and Pharmacy "Carol Davila"-
Euroecolab, Emergency Institute for Cardiovascular Diseases "Prof. Dr. C. C. Iliescu", Sos. 
Fundeni 258, 022328 Bucharest, Romania. 
5. Department of Advanced Biomedical Sciences, Federico II University Hospital, via S. 
Pansini 5, 80131 Naples, Italy. 
6. University Hospital Padua, Paediatric Cardiology, Padua, Italy 
7. University of Rennes, CHU Rennes, Inserm, LTSI - UMR 1099, F-35000 Rennes, France. 
8. William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary 
University of London, Charterhouse Square, London, EC1M 6BQ, UK 
9. Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, 
EC1A 7BE, London, UK 
10. Fondazione Toscana G. Monasterio, Pisa, Italy. 
11. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy 
12. Cardiology, University Hospital Santa Maria, Faculty of Medicine of Lisbon University 
13. Charité Medical Faculty of the Humboldt University Berlin, ECRC, 13125 Berlin, Germany. 
14. DZHK, Partner site 13125 Berlin, Germany. 
15. Helios Clinics Berlin-Buch, Cardiology, 13125 Berlin, Germany. 
16. Centre for Cardiovascular Science, University of Edinburgh, United Kingdom  
Title Page (include all author information)
17. Department of Radiology, Centro Cardiologico Monzino IRCCS, Milan, Via Carlo Parea 4, 
Milan, Lombardy 20138, Italy. 
18. Department of Cardiology, University of Baskent, E Blok, 54. Sokak, Bahcelievler 06490, 
Ankara, Turkey. 
19. Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires 
St. Luc, Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, 
Université Catholique de Louvain, Brussels, Belgium 
20. Medical Imaging Centre, Semmelweis University, Budapest, Hungary 
21. Department of Congenital Cardiology, University Hospital Southampton NHS Foundation 
Trust, Southampton, UK 
22. Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 
Siena, Italy 
23. CHU Limoges, Hôpital Dupuytren, Service Cardiologie, Limoges F-87042, France. 
24. INSERM U1094, Univ. Limoges, CHU Limoges, IRD, U1094, GEIST, 2, rue Marcland, 87000 
Limoges, France. 
25. Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 
Vienna, Austria. 
 
Corresponding author: Prof. Thor Edvardsen, MD, PhD 
Department of Cardiology, Oslo University Hospital, 
Rikshospitalet 
Sognsvannsveien 20, 0372 Oslo, Norway / PO Box 4950 
Nydalen, NO-0424 Oslo, Norway 




COVID -19 pandemic and cardiac imaging. EACVI recommendations on 
precautions, indications, prioritisation and protection for patients and 
healthcare personnel.  
 
Helge Skulstad1,2, Bernard Cosyns3, Bogdan A Popescu4, Maurizio Galderisi5, Giovanni Di 
Salvo6, Erwan Donal7, Steffen Petersen8,9, Alessia Gimelli10, Kristina H Haugaa1,2, Denisa 
Muraru11, Ana G Almeida12, Jeanette Schulz-Menger13,14,15, Marc R Dweck16, Gianluca 
Pontone17, Leyla Elif Sade18, Bernhard Gerber19, Pal Maurovich-Horvat20, Tara Bharucha21, 
Matteo Cameli22, Julien Magne23,24, Mark Westwood9, Gerald Maurer25, Thor Edvardsen1,2 
 
1. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 
2. Faculty of Medicine, University of Oslo, Oslo, Norway. 
3. Centrum voor Hart en Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel, Vrij Universiteit 
van Brussel, Brussels, Belgium. 
4. Department of Cardiology, University of Medicine and Pharmacy "Carol Davila"-
Euroecolab, Emergency Institute for Cardiovascular Diseases "Prof. Dr. C. C. Iliescu", Sos. 
Fundeni 258, 022328 Bucharest, Romania. 
5. Department of Advanced Biomedical Sciences, Federico II University Hospital, via S. 
Pansini 5, 80131 Naples, Italy. 
6. University Hospital Padua, Paediatric Cardiology, Padua, Italy 
7. University of Rennes, CHU Rennes, Inserm, LTSI - UMR 1099, F-35000 Rennes, France. 
8. William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary 
University of London, Charterhouse Square, London, EC1M 6BQ, UK 
9. Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, 
EC1A 7BE, London, UK 
10. Fondazione Toscana G. Monasterio, Pisa, Italy. 
11. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy 
12. Cardiology, University Hospital Santa Maria, Faculty of Medicine of Lisbon University 
13. Charité Medical Faculty of the Humboldt University Berlin, ECRC, 13125 Berlin, Germany. 
14. DZHK, Partner site 13125 Berlin, Germany. 
15. Helios Clinics Berlin-Buch, Cardiology, 13125 Berlin, Germany. 
16. Centre for Cardiovascular Science, University of Edinburgh, United Kingdom  
 2 
17. Department of Radiology, Centro Cardiologico Monzino IRCCS, Milan, Via Carlo Parea 4, 
Milan, Lombardy 20138, Italy. 
18. Department of Cardiology, University of Baskent, E Blok, 54. Sokak, Bahcelievler 06490, 
Ankara, Turkey. 
19. Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires 
St. Luc, Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, 
Université Catholique de Louvain, Brussels, Belgium 
20. Medical Imaging Centre, Semmelweis University, Budapest, Hungary 
21. Department of Congenital Cardiology, University Hospital Southampton NHS Foundation 
Trust, Southampton, UK 
22. Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 
Siena, Italy 
23. CHU Limoges, Hôpital Dupuytren, Service Cardiologie, Limoges F-87042, France. 
24. INSERM U1094, Univ. Limoges, CHU Limoges, IRD, U1094, GEIST, 2, rue Marcland, 87000 
Limoges, France. 
25. Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 
Vienna, Austria. 
 
Corresponding author: Prof. Thor Edvardsen, MD, PhD 
Department of Cardiology, Oslo University Hospital, 
Rikshospitalet 
Sognsvannsveien 20, 0372 Oslo, Norway / PO Box 4950 
Nydalen, NO-0424 Oslo, Norway 





The coronavirus disease 2019 (COVID-19) pandemic has created new and unpredictable 
challenges for modern medicine and health care systems. Preliminary reports have 
demonstrated that older age, previous cardiovascular disease, diabetes and hypertension 
are risk factors for increased mortality.1 Data on the cardiac affinity of the virus and its 
potential and mechanisms to harm the cardiovascular system are sparse.2 3A systemic 
infection generally increases demand on the heart, and can exacerbate underlying cardiac 
conditions. When the lungs are heavily involved, as seen in COVID-19 patients, this may have 
a major impact on cardiac function, particularly that of the right ventricle.  Finally, COVID-19 
may have direct effects on the heart as may some drugs being used in its treatment.  
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for COVID-
19 and is transmitted by droplets from person to person.4 Echocardiographers in particular, 
and cardiac imagers more generally, are in close contact with patients and therefore likely to 
have high a risk of being infected. To decrease the risk of patient to patient-, patient to 
imager- and imager to patient-contamination, the indication for any cardiac imaging test 
should be carefully considered, and only those tests considered essential to patient care 
performed. 
Cardiologists and cardiology departments are heavily affected by this rapidly changing 
situation.5 The Covid-19 pandemic also increases the burden on cardiac imaging services 
generally. However, given its wide availability and key role as a bedside test, 
echocardiography is the most affected cardiac imaging modality. Common challenges faced 
by all cardiac imaging modalities during the pandemic include limited expert staff availability 
(sickness or redeployment in prioritised areas, such as intensive care units) and the risk of 
peri-procedural transmission of SARS-CoV-2 between patients and staff. The scope of these 
EACVI recommendations is to summarise how these challenges may be addressed during the 
pandemic. In particular we focus upon bold prioritisation and provide specific indications 
and recommendations on how to perform an echocardiogram during the pandemic whilst 
safeguarding both patient and staff safety. 
Some of our recommendations relating to the appropriate use of imaging modalities in the 
COVID-19 pandemic must be considered only as expert advices due to the lack of evidence-
based scientific data and the rapidly changing global situation.  
General considerations: 
For all modalities the main question is: Will undertaking this study substantially change 
patient management or be lifesaving? If yes, use the imaging modality with the best 
capability to meet the request, but consider also the safety for medical staff regarding 
exposure. It is very important that every cardiac imaging study is performed appropriately to 
minimise the risk of further dissemination of the disease. Key-point 1. 
This question needs to be considered in detail for each echocardiogram requested given the 
risk of cross-infection and the consumption of personal protective equipment. However, 
computed tomography (CT) and cardiac magnetic resonance (CMR) may also have a 
significant potential for contamination of personnel and patients, especially linked to 
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transportation, but also via direct contamination during the scan. In parallel with 
echocardiography and other imaging modalities, CMR and CT should only be performed if 
the expected information is critical for clinical management and can be justified in the face 
of the following considerations: a) risk of transportation from ICU of critically ill or high risk 
patients; b) time duration of CMR; c) Possible/significant risk of infection for professionals 
(technicians, physicians, nurses, other personnel); d) Possible/significant risk of 
contamination of equipment and facilities, leading to the need for full disinfection; e) 
whether the test is necessary to confirm the diagnosis, or whether this can be achieved 
based simply upon the clinical probability. In many countries, imaging exams for elective 
non-urgent patients have been cancelled or postponed. However, cardiac imaging is still 
being widely requested for inpatients or those presenting to the Emergency Department. 
Key-point 2. 
Indications:  
Patients with suspected or confirmed COVID-19 and no previous history of cardiac disease 
The chest radiograph is the most commonly used imaging test in COVID-19 patients, but CT 
is frequently used to confirm COVID-19 pneumonia. Whilst this might conceivably provide 
some possible synergies and opportunities to gain information about the cardiovascular 
system, this requires bespoke protocols that are not widely employed. Dedicated coronary 
CT angiography is therefore usually required. One emerging clinical issue is that numerous 
patients with pneumonia caused by COVID-19 experience elevated Troponins with and 
without signs of obstructive coronary artery disease. In this situation coronary CT 
angiography can be of great help in excluding or confirming an acute coronary syndrome if 
the clinical picture is uncertain, substituting an invasive coronary angiogram and the 
associated exposure of all the members of the cardiac catheterisation laboratory team.6 
Coronary CT angiography is also increasingly used to assess patients with chronic coronary 
syndromes, and can be considered in the COVID-19 pandemic in patients with severe 
symptoms. Another important and emerging role of CT in the pandemic is as a replacement 
for transoesophageal echocardiography (TOE) to rule out the presence of thrombus in the 
left atrial appendage before direct current (DC) cardioversion, thereby limiting operator 
exposure. Key-points 3. 
Echocardiography should not routinely be performed in patients with typical signs of COVID-
19 disease. Indeed, it should be restricted to those patients in whom it is likely to result in a 
change in management. Nevertheless many COVID-19 patients will develop a range of 
different cardiovascular manifestations which will require a bedside echocardiographic 
study.7 Moreover, there are reasons to believe that the need for echocardiography might 
expand further as we understand more about COVID-19, with early reports indicating that 
patients with established cardiovascular disease and cardiovascular risk factors have worse 
prognosis than others, and are more likely to be admitted to hospital and need respiratory 
support.1  
Dyspnoea is a typical finding in patients with cardiac disease and echocardiography may be 
indicated in the diagnostic work-up, particularly in patients with subacute onset of 
dyspnoea, oedema or cardiac murmurs and elevated cardiac biomarkers. Conversely, a 
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normal proBNP-test can frequently be used to exclude the need of an echocardiogram in 
patients with dyspnoea or oedema.   
In the intensive care unit, echocardiography has sometimes been used to routinely monitor 
the progress of certain patients.7 This should not be routinely performed in the COVID-19 
pandemic. Instead, echocardiography should be restricted to patients with cardiovascular 
instability or signs of right ventricular dysfunction or pulmonary hypertension. Lung 
ultrasound to detect COVID-19 pneumonia is also useful.8 Thickening of the pleurae, 
appearance of B-lines and lung consolidation indicates pneumonia, with pleural effusions 
rarely reported. Due to its bedside availability, scanning of the lungs by ultrasound can be 
performed as a quick diagnostic tool.  
Transthoracic echocardiography protocol: 
If transthoracic echocardiography is required to change patient management, we 
recommend a focused cardiac ultrasound study (FoCUS) as described below. The aim is to 
reduce the time exposure with the patient and to decrease the risk of contamination.9 
Handheld or smaller lap-top based scanners may have an advantage as they are easier to 
cover, clean and disinfect than larger machines with higher capability.10 At a minimum such a 
focused echocardiographic study in patients with verified or suspected COVID-19 should 
include:  
Left ventricle: Systolic global function (ejection fraction), signs of regional dysfunction, end-
diastolic cavity dimension.  
Right ventricle: Global function (Right ventricular fractional area change (RVFAC) or Tricuspid 
annular plane systolic excursion (TAPSE)), end-diastolic cavity dimension, Tricuspid 
regurgitation pressure gradient (TRP) (if possible).  
Valves: Gross signs of valvar disease, but only in cases of critical clinical importance should 
an in-depth evaluation should be considered. 
Pericardium: Thickening or effusion. 
Lung ultrasound (see below) 
ECG monitoring during imaging can be omitted and measurements should be performed 
offline to reduce exposure of contamination. If a curtailed echocardiogram is performed 
because of the COVID-19 situation, this should be stated in the report.  
 
Patients with confirmed COVID-19 and known or acute cardiac disease:  
Due to increased metabolic and haemodynamic demands, infection and concomitant fever 
acts as a cardiac stress test potentially aggravating the effects of pre-existing valve disease, 
heart muscle disease, coronary artery disease and congenital heart disease. Similar and 
additional effects can be caused by reduced oxygenation of the blood due to respiratory 
failure. This may help explain why coexisting cardiovascular disease is a negative predictor in 
COVID-19 patients.1 Clinical decision-making may be complicated in these critically ill 
patients and cardiac imaging may be decisive. However, unnecessary examinations of 
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critically ill patients should be avoided to reduce risk of contamination of personnel and 
misuse of resources. Indeed, careful consideration should be given to whether 
echocardiography and cardiac imaging will change management, including whether patients 
would be candidates for more advanced treatment strategies on the basis of the results of 
an echocardiogram. If not, the scan may be futile.  
Patients without symptoms or signs of COVID-19 but with known or acute cardiac disease:  
Clinical priorities and procedures will change during this pandemic. Echocardiography should 
therefore generally be reserved for patients with symptomatic heart disease (NYHA III-IV) in 
this phase. Routine follow-up echocardiographic studies of patients with non-severe 
symptoms or those not eligible for invasive or surgical treatment should be postponed or 
cancelled. This includes patients with stable congenital heart disease. Patients with acute 
heart failure and patients with valvar heart disease with severe symptoms such as chest 
pain, syncope and dyspnoea during daily activity should be prioritised and receive adequate 
treatment. Their prognosis without treatment is probably worse than most COVID-19 
patients.  
Acute endocarditis, with no relation to COVID-19, will also continue to appear and the 
number of patients may even increase as visits to the dentist get cancelled. Endocarditis has 
a high mortality and these patients should continue to have a high priority for 
echocardiography and treatment according to state of the art recommendations.11 If the 
patient has concomitant COVID-19, an individualised approach is necessary. 
In STEMI we recommend an LV angiogram for LV function in patients having an invasive 
revascularisation procedure. Echocardiography can then be avoided in these patients with 
the exception of those that become haemodynamically unstable or develop potential post-
STEMI complications. In unstable Non-STEMI patients with positive troponins and clinical 
signs of heart failure, echocardiography may be of importance to justify a faster invasive 
revascularisation procedure.  Patients with murmurs should undergo echocardiography to 
rule out valve disease as the cause of their chest pain presentation.  
Transoesophageal echocardiography: 
TOE might be stressful to our patients and should be avoided in most patients with ongoing 
COVID-19. The risk of contamination of equipment and personnel is also very high during the 
procedure due to droplets and aerosols containing virus. The incremental role of TOE over 
TTE should be carefully considered. This procedure should therefore be reserved for patients 
where the suspected findings are of crucial importance to confirm or exclude a diagnosis or 
to guide treatment. 
Indication for other echocardiographic methods:  
Indications for stress echocardiography, as well as for other stress imaging techniques, seem 
very limited in the COVID-19 pandemic, and should be avoided in patients with acute 
infection. Coronary CT angiography should be the preferred method if patients are being 
investigated for chronic coronary syndromes.6 Ultrasonic contrast agent may be useful in 
some patients, but should not be used in circulatory unstable or critically ill patients.12  
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Fetal echocardiography: 
It is currently unclear whether maternal infection affects the fetus, by causing either 
structural heart disease or fetal myocarditis, and therefore routine fetal echocardiography in 
infected mothers is not recommended for the indication of COVID-19 infection alone.  
However, the indications for fetal echocardiography remain the same during the pandemic, 
in that pregnancies judged to be at high risk for fetal cardiac disease need to continue to be 
referred according to local guidelines, and assessed within the appropriate time frame.13 
Counselling may be undertaken using video conferencing or other technology in order to 
reduce time in physical proximity to the patient, and the minimum number of healthcare 
professionals should attend scanning and counselling. 
Indication for other imaging methods:  
Given the acute nature of the disease, and restrictions of hospital facilities for chronic 
patients, there are probably few defined indications for coronary CT angiography, CMR or 
nuclear cardiology in patients with COVID-19 infection during the acute phase.  
Similar as for echocardiography, patients scheduled for CMR, CT and nuclear cardiology, with 
non-severe symptoms or not eligible for invasive or surgical treatment, should be 
postponed. Routine follow-up scans should be re-scheduled. A possible indication for CMR is 
the suspicion of COVID-19 myocarditis, but the clinical implication of detecting myocarditis 
in these patients is not determined. We suggest that positive troponins and myocardial 
dysfunction or severe arrhythmia not explained by other methods, may be an indication for 
acute CMR if of crucial importance for the treatment and the patient is stable enough to be 
scanned.   
Cleaning, disinfection and protection in patients with suspected or confirmed COVID-19:  
Equipment:  
All equipment used in close contact with patients has the potential to carry droplets 
containing the virus. This includes ECG-leads which should therefore be avoided when 
performing echocardiographic studies in COVID-19 patients.  
Moderately warm water and a mild detergent constitute the basis of equipment cleaning in 
all cardiac imaging machines, including the echocardiographic probe. An ordinary water-
soluble disinfectant should also be added, but not on the membrane. A non-alcoholic 
disinfectant should be used on the echocardiographic probe (please confirm with 
recommendations for each vendor). Dedicated wipes may also be used in this process. 
Protecting the echocardiographic machines with custom-made covers may be possible if 
available, but if not other protective equipment can be fashioned using local entrepreneurs 
and ingenuity. It is, however, important not to cover the screen in a way that reduces the 
view for the echocardiographer. This may reduce the quality of the study and increase scan 
duration. Similarly, the keyboard should be fully operative during the investigation. To 
facilitate the cleaning of the scanner, all additional 3D and single-Doppler probes should be 
removed before the scanning starts, if they are not needed for proper diagnosis. ECG leads 
should also be removed, although this may make the recordings of loops more difficult and 
potentially more time consuming. In high volume centres one can consider dedicating 
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separate scanners to be used exclusively for COVID-19 positive patients, that remain within 
designated COVID-19 areas. No additional disinfection procedure is necessary for a TOE 
probe as every location should have proper routines for cleaning and disinfection of these 
probes. A protective coat on the TOE probe might also be considered. 
The positioning of the patient versus the echocardiographer and the scanner may be of 
importance. Patients placed in the left lateral position with the scanner positioned on the 
right side of the bench will result in the longest possible distance between the faces of the 
patient and the echocardiographer. The contamination of airborne droplets from the patient 
to the scanner will also probably be minimized. However, the preferred patient position is 
different among echocardiographers, and these recommendations should not be a 
hindrance to perform high quality fast echocardiograms. A surgical mask on the patient will 
also reduce contamination by air droplets. 
Facilities:  
The echocardiographic study will usually be performed in the intensive care unit or in 
emergency rooms in critically ill patients. Less critical patients are usually examined in their 
ward rooms. Dedicated room(s) may be prepared in the echocardiographic lab, where 
unnecessary equipment can be removed to make the cleaning of the room as easy as 
possible. However, there is less risk of virus spread if the echocardiographer brings the 
echocardiographic machine to the patient, and the patient can remain in their isolation. 
Local factors must be considered with dedicated COVID-19 areas respected, ensuring COVID-
19 “clean” and “dirty” areas are not mixed. 
Reading and conference rooms where echocardiograms are presented on small PC-screens 
may prevent the recommended 2 metres of distance between the experts. Thus, larger 
rooms, with projectors that can present the images on large screens are recommended. 
Virtual communication technology that allows several colleagues to simultaneously visualise  
images on geographically remote screens, is the preferred solution for multidisciplinary team 
meetings. 
Healthcare personnel:  
All advice regarding personal protective equipment (PPE) should follow the internal rules in 
each institution. This will vary according to the local nature of the pandemic and the 
availability of PPE. We here offer some general advice. Repeated and thorough handwash is 
the basis of virus protection for everyone, including patients and health professionals. In 
addition to handwashing after every examination, disinfecting agents should be used on the 
hands.  
When examining a patient with confirmed or suspected COVID-19, protective clothing, hand 
gloves, headcovers, specific facemasks and eye shields must be used (Table 1). Patients 
should wear a surgical mask during imaging (Table 2). During TOE, medical protective masks 
must be used due to risk of aerosols and airborne spread (Table 3). How to adequately dress 
and undress is described in several publications and is not further described in this paper. 
When performing an echocardiogram in patients without confirmed COVID-19, surgical 
facemasks should be used in regions where the risk of virus spread is high or uncertain. Non-
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sterile hand gloves should also be used and renewed between every patient since the 
persistence of the virus on plastic is long. If the patient has low risk of infection due to low 
risk in the respective regions or has no symptoms this may be omitted, especially if there is 
shortage of face masks or hand gloves in the hospital.  
Precautions in other imaging modalities: 
Precautions for all the other imaging modalities are similar. Imagers and technologists 
should wear protective clothing, gloves and face masks while undergoing scanning, and 
patients should wear a surgical mask during imaging. The scanner, coils and ECG cables are 
mandatory for cardiac CMR and CT scans but need to be thoroughly disinfected after 
imaging (table 1). Cleaning of the scanners after imaging patients with COVID-19 infection is 
also obligatory (see above). An important strategy to reduce contamination is to reserve one 
scanner for known infected patients and another for low-risk and non-infected patients. 
Conclusion:  
The COVID-19 pandemic has forced us to reconsider how best to perform cardiac imaging in 
the right patients at the right time and how to minimise the risk of cross infection for 
imagers and patients alike. These recommendations are suggested as tools to guide good 
clinical practice during what is a turbulent period in our practice, and one that is rapidly 
changing both the premises and demands for cardiac imaging. We expect our understanding 
of how best to image patients during the COVID-19 pandemic to change rapidly and will 
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Lower risk: Patients with no symptoms, no increased risk behaviour or recent negative virus 
test or in areas with low risk of COVID-19. Moderate risk: Patients with nonspecific/unclear 
symptoms or patients without symptoms in area with moderate or high risk of COVID-19. 
Severe risk: Patients with typical symptoms or confirmed COVID-19. FFP2: Filtering 








Recommendations for patients during all imaging modalities. 
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Definition of risks of contamination, see table 1. Washing and disinfection of the TOE probe 







Important considerations in patients with suspected or confirmed COVID-19: 
 Cardiac imaging should be performed if appropriate and only if it is likely to  
substantially change patient management or be lifesaving 
 Use the imaging modality with the best capability to meet the request, but consider 
also the safety for medical staff regarding exposure 




Risks of contamination in patients with suspected or confirmed COVID-19 include: 
 Possible/significant risk of infection for professionals (technicians, physicians, nurses, 
other personnel) 
 Possible/significant risk of contamination of equipment and facilities 
 Risk of widespread contamination due to transportation from ICU of critically ill or 
high-risk patients – the echo machine should be brought to the patient 




Advice for cardiac imaging: 
 Echocardiography should not routinely be performed in patients with typical signs of 
COVID-19 disease 
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 A range of different cardiovascular manifestations can be found in COVID-19 which 
may require cardiac imaging including a bedside echocardiographic study 
 A focused cardiac ultrasound study (FoCUS) is recommended to reduce the time of 
exposure  
 The risk of contamination of equipment and personnel is very high during TOE  – 
consider repeat TTE, CT scan or CMR as alternatives 
 Chest CT is frequently used to confirm COVID-19 pneumonia and might provide 
possible synergies and opportunities of cardiac imaging 
 Coronary CT angiography can exclude or confirm an acute coronary syndrome in 
COVID-19 pneumonia where elevated Troponins are common 
 LV function can be assessed by LV angiogram in patients with acute coronary 
syndromes during the invasive revascularisation procedure 
 Positive troponins and myocardial dysfunction or severe arrhythmia suggestive of 
Tako-tsubo or myocarditis, may be an indication for acute CMR if of vital importance 
for treatment and patient can be safely transferred for imaging 
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